...
首页> 外文期刊>Journal of the American College of Cardiology >Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries.
【24h】

Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries.

机译:在患病的大隐静脉移植物和含血栓的冠状动脉经皮介入之前,对血栓切除术进行前瞻性,随机评估。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVES: We sought to determine whether routine thrombectomy prior to stent implantation in diseased saphenous vein grafts (SVGs) and thrombus-containing native coronary arteries would reduce peri-procedural myonecrosis and subsequently enhance event-free survival. BACKGROUND: Percutaneous coronary intervention in diseased SVGs and thrombotic native coronary arteries is complicated by a high rate of peri-procedural myocardial infarction (MI). Thrombectomy prior to intervention may enhance the safety of intervention and improve early and late outcomes in these high-risk patients. METHODS: At 60 centers in the U.S. and Canada, 797 patients with 839 diseased SVGs or thrombus-containing native coronary arteries were prospectively randomized to stent implantation with versus without prior thrombectomy with the X-SIZER device (ev3, Plymouth, Minnesota). RESULTS: Peri-procedural MI occurred in 15.8% of patients assigned to the X-SIZER device compared with 16.6% of control patients (p = 0.77), although the rate of large MI (pre-specified as the development of new pathologic Q waves or creatine phosphokinase-MB isoenzyme elevation >8 x upper limits of normal) was reduced with X-SIZER device use from 9.6% to 5.5% (multivariate risk ratio 0.35 [95% confidence interval 0.18 to 0.66], p = 0.002). Major adverse cardiac events (cardiac death, MI, or repeat target vessel revascularization) occurred in 16.8% of X-SIZER patients versus 17.1% of control patients at 30 days (p = 0.92), and in 31.3% of X-SIZER patients versus 28.2% of control patients at 1 year (p = 0.35). CONCLUSIONS: Thrombectomy with the X-SIZER device prior to stent implantation in high-risk diseased SVGs and thrombus-containing native coronary arteries may reduce the extent, but not the occurrence, of myonecrosis. Early and late event-free survival, however, were not improved by routine thrombectomy with this device.
机译:目的:我们试图确定在患病的大隐静脉移植物(SVG)和含血栓的天然冠状动脉支架植入之前常规的血栓切除术是否会减少围手术期肌坏死并随后提高无事件生存率。背景:经皮冠状动脉介入治疗患病的SVG和血栓形成的天然冠状动脉,由于围手术期心肌梗死(MI)的发生率较高而变得复杂。在这些高风险患者中,在进行干预之前进行血栓切除术可以提高干预的安全性并改善早期和晚期结果。方法:在美国和加拿大的60个中心,前瞻性将797例839病态SVG或含血栓的天然冠状动脉患者随机分配至支架植入术,与不使用X-SIZER设备(ev3,Plymouth,Minnesota)进行血栓切除术相比。结果:X-SIZER装置的患者发生围手术期MI的比例为15.8%,而对照组为16.6%(p = 0.77),尽管大MI的发生率(预先指定为新的病理性Q波的发展)或使用X-SIZER设备将肌酸磷酸激酶-MB同工酶升高> 8 x正常上限降低了9.6%至5.5%(多元风险比0.35 [95%置信区间0.18至0.66],p = 0.002)。在30天时,发生严重心脏不良事件(心脏死亡,心肌梗死或重复靶血管重建)的X-SIZER患者为16.8%,对照组为17.1%(p = 0.92),X-SIZER患者为31.3% 1年时有28.2%的对照患者(p = 0.35)。结论:在高风险患病的SVG和含血栓的天然冠状动脉支架植入之前,使用X-SIZER装置进行血栓切除术可能会减少但不发生心肌坏死的程度。然而,使用该装置进行常规血栓切除术并不能改善早期和晚期无事件生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号